Oxford Pharm Gp Share Discussion Threads

[melodrama] 20/5/2013 14:28

I think largest daily volume in whole history, in terms of Value!

[doodlebug4] 20/5/2013 13:12

Looks as if there may be the sniff of another RNS - volumes picking up today.

[melodrama] 20/5/2013 12:16

Agree Nigel, he does not strike me as dim, just interested to know other of his other holdings! If he has any.

[gnnmartin] 20/5/2013 12:13

timbo said earlier that he didn't own any OXP. That's no reason to dismiss what he says though.

timbo, your reference tells us that Voltarol does not claim on the label to have fewer side effects, but that does not mean they do not (have fewer). That may sound like a sophistry, but to make a claim on the label they would have had to run a very expensive double blind trial. Without the trial, and without the claim, they can still hope to grow their market if users who have problems with other NSAIDs find the problems less severe when they switch to Voltarol.

You imply that the mechanism which OXP hope to exploit is similar to and no more effective than that used in Voltarol. I don't know enough to comment, but I would be interested to know more on that. If I can manage to get to the AGM, I'll ask there.
Nigel Martin

[melodrama] 20/5/2013 11:26

timbo003, do you own any?

[burbelly] 20/5/2013 09:20

Quietly hitting all time high

[timbo003] 15/5/2013 22:09

I think the N+1 analyst, Sheena Berry, needs to do some homework on NSAIDs before she puts out her next note.

Even if you put an enteric coat on an NSAID such as diclofenac (which is very similar to ibuprofen with wrt its pharmacological action) you still get the same GI side effects as a standard tablet

The GI warning label in the SPC for Voltarol tablets (diclofenac with an enteric coat)

is exactly the same as for the GI warning label in the SPC for Voltarol Rapid tablets (diclofenac without an enteric coat)


If an enteric coat (which prevents any contact of an NSAID with the stomach and upper duodenum) does not prevent GI side effects, what hope does mixing a bit of fructan gel (i.e. OXPzero) into a NSAID formulation have in preventing GI side effects?

[burbelly] 15/5/2013 15:01

9p would be good to begin with

[lucky_punter] 15/5/2013 14:19

Oxford Pharmascience price target raised 33% by N+1 Singer
By Ian Lyall May 15 2013, 1:56pm


According to the NHS, ibuprofen can cause a number of side effects, including nausea, vomiting, diarrhoea, indigestion and abdominal pain.
City broker N+1 Singer has raised its valuation of Oxford Pharmascience (LON:OXP) by 33% to reflect the potential of its adaptation of a top selling painkiller.

[burbelly] 14/5/2013 20:52

some odd trades on here the last few days, 2x500k and a 4mill today, 10millon Friday, mostly in pairs, any ideas? Maybe see a change of holding soon.

[doodlebug4] 10/5/2013 15:10

Interesting flurry of large O trades this afternoon and the share price didn't budge!

[burbelly] 10/5/2013 14:14

wtf? some kind of transfer?

[timbo003] 08/5/2013 21:53

I would be very cautious about reading anything into the mouse data for OXPzero ibuprofen.

I do not doubt that the OXPzero does a reasonable job on taste masking ibuprofen, but the GI side effects for NSAIDs have been seen after parenteral administration, so they are not necessarily formulation specific for orally administered drug. Furthermore, there have been many different pharmtech developments over the years, regarding attempts to reduce the GI irritancy of NSAIDs following oral administration, some of which have reached the market, however, none of them have a label claim for improved GI tolerability as far as I am aware.

On a related subject, I think the patent application concerning OXPzero with ibuprofen is this one:

[doodlebug4] 08/5/2013 15:44

Oxford Pharmascience surges on ibuprofen test results
By John Harrington May 08 2013, 11:42am Oxford's technology could allow for higher dosages of ibuprofen without the stomach irritation that often accompanies chronic consumption.

Tests on laboratory mice have given a big boost to Oxford Pharmacience's (LON:OXP) OXPzero technology.

As anyone who has read the small print on the back of a packet of Ibuprofen will know, one of the major drawbacks to taking the medicine, and other non-steroidal anti-inflammatory drugs (NSAIDs), is the possibility of gastric irritation (GI).

A recent pharmacological study in mice has demonstrated that OXPZero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

The tests indicate that Oxford's OXPzero technology may have a bigger future in the lucrative NSAIDs market worldwide than previously thought.

NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day and annual sales of US$12 billion, but the market could be bigger still if a company can crack the problem of GI side effects. These side effects include ulcers and bleeding and lead to significant morbidity and mortality in many patients.

New versions of other popular NSAIDs such as diclofenac, naproxen and aspirin will also be developed.

One of the advantages of Oxford Pharma's focus on out of patent or nearly out of patent drugs is that the bulk of the drug development and regulatory hoop-jumping has been done, which means Oxford's development programmes are comparatively inexpensive and swift. As such, a full range of OXPzero safer NSAIDs could be on the market as early as 2016.

Shares in Oxford Pharmascience shot up 6.2% to 4.01p on the news.

[melodrama] 08/5/2013 12:36

Looks like Mice can look forward to reduced hangover pain and no tummy upsets ;-)

[doodlebug4] 08/5/2013 11:54

Oxford Pharmascience Group PLC
08 May 2013
Oxford Pharmascience Group plc
("Oxford Pharmascience" or "the Company")
Oxford Pharmascience announces successful study indicating reduced gastric irritation for OXPzero(TM) ibuprofen and initiates Safer NSAIDs programme
Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces that it has established animal proof of concept and is starting a programme to develop safer NSAIDs applying its proprietary OXPzero(TM) technology.
There is a strong pharmacological rationale for reduced gastric irritation for NSAIDs delivered via the OXPzero(TM) technology and the company has demonstrated via a pharmacological study in mice that its OXPZero Ibuprofen material significantly reduces the irritation and ulcerating damage of ibuprofen. This is an exciting development for the company's technology as this shows that OXPzero(TM) has a much wider application in the field of NSAIDs to produce safer NSAID drugs.
NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day and annual sales of $12 billion. In spite of this commercial success, chronic use of NSAIDs causes well documented gastrointestinal (GI) side effects. These side effects include ulcers and bleeding and lead to significant morbidity and mortality in many patients.
Nigel Theobald, Chief Executive Officer of Oxford Pharmascience commented,
"We will now use this breakthrough in our research to begin a programme to develop a range of safer NSAIDs with much lower gastric irritation. OXPzero has already been developed for ibuprofen and will now be incorporated into high dose tablet formats of 400mg and above.
New versions of other popular NSAIDs such as diclofenac, naproxen and aspirin will also be developed.
By re-formulating existing NSAIDs which are bio-equivalent we avoid the need for expensive and lengthy new drug development to combat the gastric problem. This is at the core of all we do and further demonstration that by re-developing existing drugs to make them safer or easier to take, we can access the high value returns associated with new drugs but for a fraction of the cost and with a much quicker timescale."

[alchemy30] 08/5/2013 11:35

news out !

[timbo003] 08/5/2013 09:23

I'm just interested, but I have no financial stake in the company, so I'll pass on that one.

[burbelly] 08/5/2013 09:13

why dont you ask them?

[timbo003] 08/5/2013 09:03

A market cap of £35M looks expensive to me for a company who's only commercially validated technology is taste masking for which they received sales last year of under £0.5M

The Statin developments are very blue sky and must have an exceedingly low probablility of acheiving anything, other than a high cash burn. Do OXP have a decent scientific advisory board who have looked at the Statin development? If so, do we know which experts currently are on the advisory board?

[burbelly] 08/5/2013 08:46

some news soon me thinks

[melodrama] 07/5/2013 16:04

some chunky buys toady

[burbelly] 02/5/2013 13:05

A fair few have been unloaded at 3.3 with no drop over the last 6 weeks